{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:54:21Z","timestamp":1791078861980,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2003,7]]},"DOI":"10.1067\/mjd.2003.449","type":"journal-article","created":{"date-parts":[[2003,7,16]],"date-time":"2003-07-16T18:38:44Z","timestamp":1058380724000},"page":"35-49","source":"Crossref","is-referenced-by-count":61,"title":["Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma"],"prefix":"10.1067","volume":"49","author":[{"given":"Madeleine","family":"Duvic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narin","family":"Apisarnthanarax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah S.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul S.","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1067\/mjd.2003.449_bib1","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood.V88.7.2385.bloodjournal8872385","article-title":"Mycosis fungoides and Sezary syndrome","volume":"88","author":"Diamandidou","year":"1996","journal-title":"Blood"},{"key":"10.1067\/mjd.2003.449_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/canjclin.43.2.93","article-title":"Mycosis fungoides: clinical and histologic features, staging, evaluation, and approach to treatment","volume":"43","author":"Abel","year":"1993","journal-title":"CA Cancer J Clin"},{"key":"10.1067\/mjd.2003.449_bib3","first-page":"276","article-title":"Mycosis fungoides and the Sezary syndrome","volume":"26","author":"Kim","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1067\/mjd.2003.449_bib4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0889-8588(18)30055-8","article-title":"Prognosis and staging of cutaneous T-cell lymphoma","volume":"9","author":"Foss","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1067\/mjd.2003.449_bib5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/archderm.1996.03890350051009","article-title":"Clinical stage IA (limited patch and plaque) mycosis fungoides: a long-term outcome analysis","volume":"132","author":"Kim","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2003.449_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.135.1.26","article-title":"Clinical characteristics and long-term outcome of patients with generalized patch or plaque (T2) mycosis fungoides","volume":"135","author":"Kim","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2003.449_bib7","doi-asserted-by":"crossref","first-page":"372","DOI":"10.7326\/0003-4819-109-5-372","article-title":"Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome: definition of three distinctive prognostic groups","volume":"109","author":"Sausville","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1067\/mjd.2003.449_bib8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0190-9622(99)70079-4","article-title":"Prognostic factor analysis in mycosis\/Sezary syndrome","volume":"40","author":"Diamandidou","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2003.449_bib9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0190-9622(99)70491-3","article-title":"Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients","volume":"40","author":"Zackheim","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2003.449_bib10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-121-8-199410150-00007","article-title":"Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome)","volume":"121","author":"Bunn","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1067\/mjd.2003.449_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0733-8635(05)70155-8","article-title":"Emerging new therapies for cutaneous T-cell lymphoma","volume":"18","author":"Duvic","year":"2000","journal-title":"Dermatol Clin"},{"key":"10.1067\/mjd.2003.449_bib12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0733-8635(05)70312-0","article-title":"CTCL: new immunomodulators","volume":"19","author":"Apisarnthanarax","year":"2001","journal-title":"Dermatol Clin"},{"key":"10.1067\/mjd.2003.449_bib13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1586\/14737140.1.3.403","article-title":"Therapy options in cutaneous T-cell lymphoma","volume":"1","author":"Apisarnthanarax","year":"2001","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1067\/mjd.2003.449_bib14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/00128071-200203030-00006","article-title":"Treatment of cutaneous T cell lymphoma: current status and future directions","volume":"3","author":"Apisarnthanarax","year":"2002","journal-title":"Am J Clin Dermatol"},{"key":"10.1067\/mjd.2003.449_bib15","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0889-8588(18)30057-1","article-title":"Topical treatment of early cutaneous T-cell lymphoma","volume":"9","author":"Ramsay","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1067\/mjd.2003.449_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2340\/00015555655358","article-title":"Topical nitrogen mustard in early mycosis fungoides: a 12-year experience","volume":"65","author":"Zachariae","year":"1985","journal-title":"Acta Derm Venereol"},{"key":"10.1067\/mjd.2003.449_bib17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0190-9622(89)70051-7","article-title":"Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T-cell lymphoma","volume":"20","author":"Vonderheid","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2003.449_bib18","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0190-9622(88)70223-6","article-title":"Topical mechlorethamine therapy for early stage mycosis fungoides","volume":"19","author":"Ramsay","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2003.449_bib19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/archderm.1982.01650150012011","article-title":"Treatment of mycosis fungoides: total-skin electron-beam irradiation vs topical mechlorethamine therapy","volume":"118","author":"Hamminga","year":"1982","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2003.449_bib20","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0360-3016(98)00517-3","article-title":"Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides","volume":"43","author":"Chinn","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1067\/mjd.2003.449_bib21","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1002\/1097-0142(197712)40:6<2851::AID-CNCR2820400615>3.0.CO;2-X","article-title":"The treatment of mycosis fungoides: adjuvant topical mechlorethamine after electron beam therapy","volume":"40","author":"Price","year":"1977","journal-title":"Cancer"},{"key":"10.1067\/mjd.2003.449_bib22","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0889-8588(18)30060-1","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"9","author":"Olsen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1067\/mjd.2003.449_bib23","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-101-4-484","article-title":"Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas","volume":"101","author":"Bunn","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1067\/mjd.2003.449_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ijc.2910390704","article-title":"Recombinant interferon alfa-2a, an active agent in advanced cutaneous T-cell lymphoma","volume":"1","author":"Bunn","year":"1987","journal-title":"Int J Cancer"},{"key":"10.1067\/mjd.2003.449_bib25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2133.1989.tb15526.x","article-title":"Low dose recombinant interferon-alpha in the treatment of cutaneous T-cell lymphoma","volume":"121","author":"Dreno","year":"1989","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2003.449_bib26","first-page":"549","article-title":"Treatment of cutaneous T-cell lymphoma with recombinant alfa 2B inteferon","volume":"93","author":"Estrach","year":"1989","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mjd.2003.449_bib27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(89)70049-9","article-title":"Interferon alfa-2a in the treatment of cutaneous T-cell lymphoma","volume":"20","author":"Olsen","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2003.449_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.1990.tb00903.x","article-title":"Interferon alpha-2a in cutaneous T-cell lymphoma","volume":"52","author":"Vegna","year":"1990","journal-title":"Eur J Haematol"},{"key":"10.1067\/mjd.2003.449_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.1990.8.1.155","article-title":"Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sezary syndrome","volume":"8","author":"Kohn","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1067\/mjd.2003.449_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0609.1988.tb00793.x","article-title":"Low dose alpha interferon treatment in patients with advanced cutaneous T-cell lymphoma","volume":"40","author":"Hagberg","year":"1988","journal-title":"Eur J Haematol"},{"key":"10.1067\/mjd.2003.449_bib31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000248098","article-title":"Treatment of cutaneous T cell lymphoma with intermediate doses of interferon alpha 2a","volume":"179","author":"Nicolas","year":"1989","journal-title":"Dermatologica"},{"key":"10.1067\/mjd.2003.449_bib32","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/archderm.1987.01660300079016","article-title":"Recombinant interferon alfa-2b in plaque-phase mycosis fungoides","volume":"123","author":"Vonderheid","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2003.449_bib33","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1365-2133.1988.tb02600.x","article-title":"Treatment of mycosis fungoides with recombinant interferon-alpha2a alone and in combination with etretinate","volume":"118","author":"Thestrup-Pederson","year":"1988","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2003.449_bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-0609.1993.tb01595.x","article-title":"Interferon treatment of cutaneous T-cell lymphoma","volume":"51","author":"Ross","year":"1993","journal-title":"Eur J Haematol"},{"key":"10.1067\/mjd.2003.449_bib35","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2133.1999.02704.x","article-title":"Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa","volume":"140","author":"Jumbou","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2003.449_bib36","first-page":"15","article-title":"Treatment of cutaneous T cell lymphoma with retinoids","volume":"7","author":"Zackheim","year":"1998","journal-title":"Dermatol Ther"},{"key":"10.1067\/mjd.2003.449_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/archderm.1987.01660260071016","article-title":"Isotretinoin and cutaneous helper-T-cell lymphoma (mycosis fungoides)","volume":"123","author":"Kessler","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2003.449_bib38","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2133.1991.tb14772.x","article-title":"The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alfa2a and etretinate","volume":"125","author":"Dreno","year":"1991","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2003.449_bib39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0190-9622(91)70036-2","article-title":"Treatment of cutaneous T-cell lymphoma with combination of low-dose interferon-2b and retinoids","volume":"24","author":"Knobler","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2003.449_bib40","first-page":"580","article-title":"Treatment of mycosis fungoides with recombinant alpha 2B interferon in combination with etretinate","volume":"93","author":"Stravrianeas","year":"1989","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mjd.2003.449_bib41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/cbr.1996.11.21","article-title":"Biological modifiers (etretinate and alfa 2a) in the treatment of refractory cutaneous T-cell lymphoma","volume":"11","author":"Aviles","year":"1996","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1067\/mjd.2003.449_bib42","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0889-8588(18)30058-3","article-title":"Electron beam treatment for cutaneous T-cell lymphoma","volume":"9","author":"Jones","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1067\/mjd.2003.449_bib43","first-page":"691","article-title":"Electron beam therapy for mycosis fungoides: the Stanford University experience","volume":"63","author":"Hoppe","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1067\/mjd.2003.449_bib44","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/0360-3016(83)90258-4","article-title":"Total skin electron irradiation for mycosis fungoides: failure analysis and prognostic factors","volume":"9","author":"Tadros","year":"1983","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1067\/mjd.2003.449_bib45","first-page":"633","article-title":"Once weekly total-skin electron beam therapy for mycosis fungoides: 7 years' experience","volume":"63","author":"Nisce","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1067\/mjd.2003.449_bib46","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/0360-3016(95)00073-8","article-title":"Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy","volume":"32","author":"Wilson","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1067\/mjd.2003.449_bib47","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0360-3016(94)90103-1","article-title":"Prognosis with newly diagnosed mycosis fungoides after total skin electron radiation of 30 or 35 Gy","volume":"28","author":"Jones","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1067\/mjd.2003.449_bib48","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0190-9622(89)70251-6","article-title":"Low-dose methotrexate for the Sezary syndrome","volume":"21","author":"Zackheim","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2003.449_bib49","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00000421-198410000-00012","article-title":"Combination chemotherapy for mycosis fungoides with cyclophosphamide, vincristine, methotrexate, and prednisone","volume":"7","author":"Case","year":"1984","journal-title":"Am J Clin Oncol"},{"key":"10.1067\/mjd.2003.449_bib50","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8","article-title":"Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma","volume":"86","author":"Akpek","year":"1999","journal-title":"Cancer"},{"key":"10.1067\/mjd.2003.449_bib51","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000246116","article-title":"Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma","volume":"194","author":"Fierro","year":"1997","journal-title":"Dermatology"},{"key":"10.1067\/mjd.2003.449_bib52","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0889-8588(18)30061-3","article-title":"Chemotherapy for mycosis fungoides and the Sezary syndrome","volume":"9","author":"Rosen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1067\/mjd.2003.449_bib53","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S0190-9622(96)90282-0","article-title":"Combined modality therapy for cutaneous T-cell lymphoma","volume":"34","author":"Duvic","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2003.449_bib54","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/cpt196126709","article-title":"Meaningful clinical classification of therapeutic response to anti-cancer drugs","volume":"2","author":"Karnofsky","year":"1961","journal-title":"Clin Pharmacol Ther"},{"key":"10.1067\/mjd.2003.449_bib55","doi-asserted-by":"crossref","first-page":"187","DOI":"10.7326\/0003-4819-100-2-187","article-title":"Clinical staging for cutaneous T-cell lymphoma","volume":"100","author":"Lamberg","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1067\/mjd.2003.449_bib56","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0190-9622(98)70597-3","article-title":"Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma","volume":"38","author":"Vonderheid","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2003.449_bib57","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/1523-1747.ep12389114","article-title":"Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides\/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR\/DGGE)","volume":"103","author":"Wood","year":"1994","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mjd.2003.449_bib58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0360-3016(97)00585-3","article-title":"Utililization of thermoluminescent dosimetry in total skin electron beam radiotherapy of mycosis fungoides","volume":"40","author":"Antolak","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1067\/mjd.2003.449_bib59","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy","volume":"316","author":"Edelson","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1067\/mjd.2003.449_bib60","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0889-8588(18)30056-X","article-title":"Assessing clinical outcomes in cutaneous T-cell lymphoma","volume":"9","author":"Zackheim","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1067\/mjd.2003.449_bib61","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/archderm.1978.01640130027008","article-title":"Radiation dermatitis following electron beam therapy: an evaluation of patients ten years after total skin irradiation for mycosis fungoides","volume":"114","author":"Price","year":"1978","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2003.449_bib62","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/1097-0142(197212)30:6<1505::AID-CNCR2820300614>3.0.CO;2-L","article-title":"Combination chemotherapy and radiotherapy for Hodgkin's disease","volume":"30","author":"Rosenberg","year":"1972","journal-title":"Cancer"},{"key":"10.1067\/mjd.2003.449_bib63","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1067\/mjd.2003.449_bib64","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.1988.6.7.1177","article-title":"Combined modality therapy for tumor stage mycosis fungoides: results of a 10-year follow-up","volume":"6","author":"Hallahan","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1067\/mjd.2003.449_bib65","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.1986.4.7.1094","article-title":"Combined modality treatment of cutaneous T-cell lymphoma: results of a 6-year follow-up","volume":"4","author":"Winkler","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1067\/mjd.2003.449_bib66","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0190-9622(87)70004-8","article-title":"Combined total body electron beam irradiation and chemotherapy for mycosis fungoides","volume":"16","author":"Braverman","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2003.449_bib67","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V92.4.1150","article-title":"Transformation of mycosis fungoides\/Sezary syndrome: clinical characteristics and prognosis","volume":"92","author":"Diamandidou","year":"1998","journal-title":"Blood"},{"key":"10.1067\/mjd.2003.449_bib68","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jnci\/82.3.235","article-title":"Low-versus high-dose inferferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma","volume":"82","author":"VanderMolen","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1067\/mjd.2003.449_bib69","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/archderm.1982.01650150041020","article-title":"Acute myeloblastic leukemia following chemotherapy for mycosis fungoides","volume":"118","author":"Waddell","year":"1982","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2003.449_bib70","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(19831215)52:12<2214::AID-CNCR2820521207>3.0.CO;2-H","article-title":"Ointment-based mechlorethamine treatment for mycosis fungoides","volume":"52","author":"Price","year":"1983","journal-title":"Cancer"},{"key":"10.1067\/mjd.2003.449_bib71","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2003.449_bib72","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1067\/mjd.2003.449_bib73","first-page":"7","article-title":"Immunotoxin DAB389-interleukin 2 (Ontak) in the management of cutaneous T-cell lymphoma","volume":"2","author":"Duvic","year":"1999","journal-title":"Curr Pract Med"},{"key":"10.1067\/mjd.2003.449_bib74","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1067\/mjd.2003.449_bib75","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1067\/mjd.2003.449_bib76","first-page":"58","article-title":"Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies","volume":"27","author":"Foss","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1067\/mjd.2003.449_bib77","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.1999.17.10.3117","article-title":"Pentostatin therapy of T-cell lymphomas with cutaneous manifestations","volume":"17","author":"Kurzrock","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1067\/mjd.2003.449_bib78","first-page":"1","article-title":"Extracorporeal photochemotherapy","volume":"4","author":"Edelson","year":"1994","journal-title":"Biol Ther Cancer Upd"},{"key":"10.1067\/mjd.2003.449_bib79","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0889-8588(18)30062-5","article-title":"Photopheresis for the treatment of cutaneous T-cell lymphoma","volume":"9","author":"Lim","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1067\/mjd.2003.449_bib80","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1067\/mjd.2000.105510","article-title":"Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides","volume":"43","author":"Wilson","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2003.449_bib81","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II","volume":"92","author":"Stadler","year":"1998","journal-title":"Blood"},{"key":"10.1067\/mjd.2003.449_bib82","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM199704103361501","article-title":"Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA): the PUVA follow-up study","volume":"336","author":"Stern","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1067\/mjd.2003.449_bib83","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0190-9622(95)90241-4","article-title":"Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up","volume":"33","author":"Hermann","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2003.449_bib84","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/archderm.1995.01690160060009","article-title":"Malignant melanoma and other second cutaneous malignanacies in cutaneous T-cell lymphoma: the influence of additional therapy after total skin electron beam radiation","volume":"131","author":"Licata","year":"1995","journal-title":"Arch Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962203008053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962203008053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T08:51:48Z","timestamp":1704876708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962203008053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["S0190962203008053"],"URL":"https:\/\/doi.org\/10.1067\/mjd.2003.449","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2003,7]]}}}